| Acute ischemic stroke therapy. | |
| | |
MedLine Citation:
|
PMID: 20936925 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Data from the European Cooperative Acute Stroke Study (ECASS) III trial demonstrated that tissue plasminogen activator given up to 4.5 h after stroke onset improves outcome and treatment guidelines support its use during this time window. Intra-arterial therapy with tissue plasminogen activator or devices is commonly used at large tertiary centers up to 6–8 h after stroke onset, but conclusive evidence of efficacy remains lacking. During the acute phase after stroke onset, blood pressure elevations should be reduced as should substantial elevations in blood glucose. Statins are recommended in essentially all non-cardioembolic stroke patients. The most important future directions for acute stroke therapy are to extend the therapeutic time window and to increase the proportion of patients treated within the currently documented 4.5-h time window. Imaging-guided selection of appropriate patients will likely be a key factor for extending the therapeutic time window and both diffusion/perfusion MRI and perfusion computed tomography will be useful imaging modalities in this effort. |
| | |
Authors:
|
Nils Henninger; Rajat Kumar; Marc Fisher |
Related Documents
:
|
7529685 - Somatosensory evoked magnetic fields in patients with stroke. 16833055 - Multimodal use of computed tomography in early acute stroke, part 1. 15716525 - Early computed tomography features in extensive middle cerebral artery territory infarc... 11480245 - Sensitivity of diffusion-weighted magnetic resonance imaging in the diagnosis of acute ... 6761515 - Conventional roentgen diagnosis of mediastinal lymphadenopathy. review article (part one). 16534255 - Intraoperative neuronavigation using diffusion tensor mr tractography for the resection... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert review of cardiovascular therapy Volume: 8 ISSN: 1744-8344 ISO Abbreviation: Expert Rev Cardiovasc Ther Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-10-12 Completed Date: 2011-01-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101182328 Medline TA: Expert Rev Cardiovasc Ther Country: England |
Other Details:
|
Languages: eng Pagination: 1389-98 Citation Subset: IM |
Affiliation:
|
Department of Neurology, University of Massachusetts Medical Center, 55 Lake Avenue, North Worcester, MA 01655, USA. nils.henninger@umassmemorial.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Animals Blood Glucose Blood Pressure Brain Ischemia / drug therapy*, physiopathology Fibrinolytic Agents / administration & dosage* Humans Practice Guidelines as Topic Stroke / drug therapy*, physiopathology Time Factors Tissue Plasminogen Activator / administration & dosage* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Fibrinolytic Agents; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The impact of catheter-tracking technologies on efficacy and safety in cardiac electrophysiology.
Next Document: Timing of carotid surgery after acute stroke.